Literature DB >> 11992688

Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector.

Zhi-Li Xu1, Hiroyuki Mizuguchi, Akiko Ishii-Watabe, Eriko Uchida, Tadanori Mayumi, Takao Hayakawa.   

Abstract

In studies of both gene function and gene therapy, transgene expression may be assisted considerably through the use of transcriptional regulatory elements with high activity. In this study, we evaluated the strength of various transcriptional regulatory elements both in vitro (six types of cell line) and in vivo (mouse heart, lung, kidney, spleen, and liver) by adenovirus-mediated gene transfer. In the case of the promoter/enhancer (P/E), the activity of CMV P/E (from the human cytomegalovirus immediate-early 1 gene) and hybrid CA P/E (composed of the CMV enhancer and chicken beta-actin promoter) were investigated, both of which are known to be strong and widely used. While hybrid CA P/E showed a higher transgene expression activity than CMV P/E, the addition of the intron A sequence (the largest intron of CMV) to CMV P/E increased the activity of CMV P/E to the same or higher level than that of hybrid CA P/E. Concerning the polyadenylation signal (P(A)) sequence, one from the bovine growth hormone (BGH) gene was about two times more efficient than that from the Simian virus 40 (SV40) late gene, both in vitro and in vivo. In the context of the CMV P/E containing the intron A sequence, a further increase in transgene expression was obtained by the addition of a SV40 enhancer downstream from the P(A) sequence. The combination of the SV40 P(A) and a SV40 enhancer showed almost comparable activity to BGH P(A). This information would be helpful for the construction of adenovirus vectors for studies regarding both gene function and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992688     DOI: 10.1016/s0168-3659(02)00059-7

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  13 in total

1.  Toward more efficient protein expression: keep the message simple.

Authors:  Stephan Kalwy; James Rance; Robert Young
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

2.  Modified MHC Class II-Associated Invariant Chain Induces Increased Antibody Responses against Plasmodium falciparum Antigens after Adenoviral Vaccination.

Authors:  Cyrielle Fougeroux; Louise Turner; Anders Miki Bojesen; Thomas Lavstsen; Peter Johannes Holst
Journal:  J Immunol       Date:  2019-03-04       Impact factor: 5.422

Review 3.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

Review 4.  Non-viral therapeutic approaches to ocular diseases: An overview and future directions.

Authors:  Rahel Zulliger; Shannon M Conley; Muna I Naash
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

5.  Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.

Authors:  Kathlyn Santos; Cindy M P Duke; Sol M Rodriguez-Colon; Anthony Dakwar; Shongshan Fan; Michael C Keefer; Howard J Federoff; John G Frelinger; William J Bowers; Stephen Dewhurst
Journal:  Vaccine       Date:  2006-11-15       Impact factor: 3.641

6.  Including the p53 ELAV-like protein-binding site in vector cassettes enhances transgene expression in rat submandibular gland.

Authors:  C Zheng; B J Baum
Journal:  Oral Dis       Date:  2012-01-18       Impact factor: 3.511

7.  Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.

Authors:  Zhili Xu; Qi Qiu; Jie Tian; Jeffrey S Smith; Gina M Conenello; Takashi Morita; Andrew P Byrnes
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

8.  Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer.

Authors:  H Sawahara; H Shiraha; D Uchida; H Kato; T Nagahara; M Iwamuro; J Kataoka; S Horiguchi; M Watanabe; M Sakaguchi; A Takaki; K Nouso; Y Nasu; H Kumon; H Okada
Journal:  Cancer Gene Ther       Date:  2016-07-29       Impact factor: 5.987

9.  A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector.

Authors:  Masami Watanabe; Masakiyo Sakaguchi; Rie Kinoshita; Haruki Kaku; Yuichi Ariyoshi; Hideo Ueki; Ryuta Tanimoto; Shin Ebara; Kazuhiko Ochiai; Junichiro Futami; Shun-Ai Li; Peng Huang; Yasutomo Nasu; Nam-Ho Huh; Hiromi Kumon
Journal:  Oncol Rep       Date:  2013-12-31       Impact factor: 3.906

10.  A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy.

Authors:  Tetsuo Oka; Kazuhiko Kurozumi; Yosuke Shimazu; Tomotsugu Ichikawa; Joji Ishida; Yoshihiro Otani; Toshihiko Shimizu; Yusuke Tomita; Masakiyo Sakaguchi; Masami Watanabe; Yasutomo Nasu; Hiromi Kumon; Isao Date
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.